Efficacy of Positive Expiratory Pressure on Acute Mountain Sickness

NCT ID: NCT07148674

Last Updated: 2025-08-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

3 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-09-05

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This pilot study aims to evaluate the efficacy of positive expiratory pressure (PEP) therapy at 10 cmH₂O in improving peripheral oxygen saturation (SpO₂) and mitigating symptoms of acute mountain sickness (AMS) in healthy individuals exposed to extreme altitude conditions.

Three male participants will be monitored during an ascent of Mount Aconcagua, Argentina, at elevations of 4,300 m, 5,560 m, and 6,000 m above sea level. The study involves three sequential phases of 10 minutes each: baseline breathing without PEP, breathing with PEP applied via a mechanical face mask, and post-PEP breathing.

Primary outcomes include changes in SpO₂ and Lake Louise Score (LLS) to assess AMS severity. Findings will provide preliminary data on the potential role of PEP as a non-pharmacological intervention in high-altitude medicine.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Mountain Sickness (AMS)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intervention

Pilot trial of positive expiratory pressure for acute mountain sickness.

1 single arm with 3 phases:

* 1: Baseline Breathing (No PEP) Participants breathe normally without any device for 10 minutes in supine position, serving as control.
* 2: Positive Expiratory Pressure (PEP) Breathing Participants breathe through a face mask with a mechanical PEP device set at 10 cmH₂O expiratory pressure for 10 minutes supine. Inspiration is unrestricted; expiration occurs against resistance to improve oxygenation and reduce AMS symptoms.
* 3: Post-PEP Breathing (No PEP) After PEP, participants breathe normally for 10 minutes supine.

Each phase is consecutive at altitudes 4,300 m, 5,560 m, and 6,000 m

Group Type EXPERIMENTAL

Positive Expiratory Pressure (10cmH2O) in hypobaric hypoxia

Intervention Type DEVICE

The intervention under investigation will be the application of positive expiratory pressure (PEP) at 10 cmH₂O using an Ambu mask. The mask will allow participants to inspire freely while generating a controlled expiratory pressure. The PEP device is a non-pharmacological medical device whose uses in both hospital and pre-hospital settings are part of everyday medical practice.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Positive Expiratory Pressure (10cmH2O) in hypobaric hypoxia

The intervention under investigation will be the application of positive expiratory pressure (PEP) at 10 cmH₂O using an Ambu mask. The mask will allow participants to inspire freely while generating a controlled expiratory pressure. The PEP device is a non-pharmacological medical device whose uses in both hospital and pre-hospital settings are part of everyday medical practice.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy volunteers without ongoing medical conditions
* Over 18 years of age
* Volunteers with the physical and technical skills necessary to undertake a mountaineering expedition on Mount Aconcagua, Argentina, and with previous experience at extreme altitudes

Exclusion Criteria

* Subjects with any ongoing medical conditions
* Under 18 years of age
* Subjects without previous mountaineering experience at extreme altitudes and without adequate physical and technical preparation necessary to undertake a mountaineering expedition on Mount Aconcagua, Argentina
Minimum Eligible Age

18 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Società Italiana Medicina degli Ambienti Estremi

UNKNOWN

Sponsor Role collaborator

BiALP - Alpine, Disaster and Wilderness Medicine

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Paolo Rodi

MD, MScMD, principal investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Paolo Rodi, MD

Role: CONTACT

Phone: +41766992164

Email: [email protected]

References

Explore related publications, articles, or registry entries linked to this study.

Mellor A. Research at high altitudes. J R Army Med Corps. 2011 Mar;157(1):5-7. doi: 10.1136/jramc-157-01-01.

Reference Type BACKGROUND
PMID: 21465903 (View on PubMed)

Wu J, Wu Y, Wang L, Ye H, Lu J, Li Y. Challenges and Advances in Rechargeable Batteries for Extreme-Condition Applications. Adv Mater. 2024 Jan;36(4):e2308193. doi: 10.1002/adma.202308193. Epub 2023 Nov 28.

Reference Type BACKGROUND
PMID: 37847882 (View on PubMed)

Nespoulet H, Rupp T, Bachasson D, Tamisier R, Wuyam B, Levy P, Verges S. Positive expiratory pressure improves oxygenation in healthy subjects exposed to hypoxia. PLoS One. 2013 Dec 23;8(12):e85219. doi: 10.1371/journal.pone.0085219. eCollection 2013.

Reference Type BACKGROUND
PMID: 24376872 (View on PubMed)

Johnson PL, Johnson CC, Poudyal P, Regmi N, Walmsley MA, Basnyat B. Continuous positive airway pressure treatment for acute mountain sickness at 4240 m in the Nepal Himalaya. High Alt Med Biol. 2013 Sep;14(3):230-3. doi: 10.1089/ham.2013.1015.

Reference Type BACKGROUND
PMID: 24067184 (View on PubMed)

Rupp T, Saugy JJ, Bourdillon N, Verges S, Millet GP. Positive expiratory pressure improves arterial and cerebral oxygenation in acute normobaric and hypobaric hypoxia. Am J Physiol Regul Integr Comp Physiol. 2019 Nov 1;317(5):R754-R762. doi: 10.1152/ajpregu.00025.2019. Epub 2019 Sep 18.

Reference Type BACKGROUND
PMID: 31530174 (View on PubMed)

Rupp T, Maufrais C, Walther G, Esteve F, Macdonald JH, Bouzat P, Verges S. MEDEX 2015: Prophylactic Effects of Positive Expiratory Pressure in Trekkers at Very High Altitude. Front Physiol. 2021 Sep 21;12:710622. doi: 10.3389/fphys.2021.710622. eCollection 2021.

Reference Type BACKGROUND
PMID: 34621182 (View on PubMed)

Fagevik Olsen M, Lannefors L, Westerdahl E. Positive expiratory pressure - Common clinical applications and physiological effects. Respir Med. 2015 Mar;109(3):297-307. doi: 10.1016/j.rmed.2014.11.003. Epub 2014 Nov 12.

Reference Type BACKGROUND
PMID: 25573419 (View on PubMed)

Gabry AL, Ledoux X, Mozziconacci M, Martin C. High-altitude pulmonary edema at moderate altitude (< 2,400 m; 7,870 feet): a series of 52 patients. Chest. 2003 Jan;123(1):49-53. doi: 10.1378/chest.123.1.49.

Reference Type BACKGROUND
PMID: 12527602 (View on PubMed)

Agostoni P, Caldara G, Bussotti M, Revera M, Valentini M, Gregorini F, Faini A, Lombardi C, Bilo G, Giuliano A, Veglia F, Savia G, Modesti PA, Mancia G, Parati G; HIGHCARE Investigators. Continuous positive airway pressure increases haemoglobin O2 saturation after acute but not prolonged altitude exposure. Eur Heart J. 2010 Feb;31(4):457-63. doi: 10.1093/eurheartj/ehp472. Epub 2009 Nov 10.

Reference Type BACKGROUND
PMID: 19903683 (View on PubMed)

Wang C, Wang X, Chi C, Guo L, Guo L, Zhao N, Wang W, Pi X, Sun B, Lian A, Shi J, Li E. Lung ventilation strategies for acute respiratory distress syndrome: a systematic review and network meta-analysis. Sci Rep. 2016 Mar 9;6:22855. doi: 10.1038/srep22855.

Reference Type BACKGROUND
PMID: 26955891 (View on PubMed)

Roach RC, Hackett PH, Oelz O, Bartsch P, Luks AM, MacInnis MJ, Baillie JK; Lake Louise AMS Score Consensus Committee. The 2018 Lake Louise Acute Mountain Sickness Score. High Alt Med Biol. 2018 Mar;19(1):4-6. doi: 10.1089/ham.2017.0164. Epub 2018 Mar 13.

Reference Type BACKGROUND
PMID: 29583031 (View on PubMed)

Luks AM, Beidleman BA, Freer L, Grissom CK, Keyes LE, McIntosh SE, Rodway GW, Schoene RB, Zafren K, Hackett PH. Wilderness Medical Society Clinical Practice Guidelines for the Prevention, Diagnosis, and Treatment of Acute Altitude Illness: 2024 Update. Wilderness Environ Med. 2024 Mar;35(1_suppl):2S-19S. doi: 10.1016/j.wem.2023.05.013. Epub 2023 Dec 27.

Reference Type BACKGROUND
PMID: 37833187 (View on PubMed)

Woods P, Alcock J. High-altitude pulmonary edema. Evol Med Public Health. 2021 Jan 6;9(1):118-119. doi: 10.1093/emph/eoaa052. eCollection 2021.

Reference Type BACKGROUND
PMID: 33732460 (View on PubMed)

Hackett PH, Rennie D, Levine HD. The incidence, importance, and prophylaxis of acute mountain sickness. Lancet. 1976 Nov 27;2(7996):1149-55. doi: 10.1016/s0140-6736(76)91677-9.

Reference Type BACKGROUND
PMID: 62991 (View on PubMed)

Netzer N, Strohl K, Faulhaber M, Gatterer H, Burtscher M. Hypoxia-related altitude illnesses. J Travel Med. 2013 Jul-Aug;20(4):247-55. doi: 10.1111/jtm.12017. Epub 2013 Mar 11.

Reference Type BACKGROUND
PMID: 23809076 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

6962

Identifier Type: -

Identifier Source: org_study_id